Soligenix (NASDAQ: SNGX) , a late-stage biopharmaceutical company targeting rare diseases, was spotlighted in a July 10 Zacks Small-Cap Research repo ...

One of the more serious side effects from immune checkpoint inhibitor (ICI) therapies for cancer is new-onset or worsened ...

A new international study led by researchers at McMaster University has identified the most effective and safest treatments ...

LEO has plans for Spevigo beyond generalised pustular psoriasis as it looks to boost its dermatological pipeline.

Boehringer Ingelheim, one of the industry leading investors in research and development in innovative life expectancy therapies, announced a $105 million (€90 million) global license and transfer ...

INGELHEIM, Germany & BALLERUP, Denmark I July 14, 2025 I Boehringer Ingelheim and LEO Pharma today announced an exclusive global license and transfer ...

A large cohort study of patients with psoriasis using wearable devices finds more exercise is associated with a lower risk ...

A new trial finds guselkumab is highly effective and well tolerated for moderate to severe scalp psoriasis in individuals ...

Inverse psoriasis, which causes painful lesions on sensitive skin folds, can be hard to treat. Find out more about this type of psoriasis.

Guselkumab and risankizumab for psoriasis have the highest rates of drug survival among biologics measured and a comparable safety profile.

John McEnroe is on the call of the men's championship match at Wimbledon on Sunday. The iconic American tennis player, who ...

Boehringer Ingelheim and LEO Pharma have signed an exclusive global license and transfer agreement to commercialize and ...